Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;15(11):585-590.
doi: 10.1200/JOP.19.00230. Epub 2019 Sep 11.

Patient Navigation in Cancer: The Business Case to Support Clinical Needs

Affiliations
Review

Patient Navigation in Cancer: The Business Case to Support Clinical Needs

Ronald M Kline et al. J Oncol Pract. 2019 Nov.

Abstract

Purpose: Patient navigation (PN) is an increasingly recognized element of high-quality, patient-centered cancer care, yet PN in many cancer programs is absent or limited, often because of concerns of extra cost without tangible financial benefits.

Methods: Five real-world examples of PN programs are used to demonstrate that in the pure fee-for-service and the alternative payment model worlds of reimbursement, strong cases can be made to support the benefits of PN.

Results: In three large programs, PN resulted in increased patient retention and increased physician loyalty within the cancer programs, leading to increased revenue. In addition, in two programs, PN was associated with a reduction in unnecessary resource utilization, such as emergency department visits and hospitalizations. PN also reduces burdens on oncology providers, potentially reducing burnout, errors, and costly staff turnover.

Conclusion: PN has resulted in improved patient outcomes and patient satisfaction and has important financial benefits for cancer programs in the fee-for-service and the alternative payment model worlds, lending support for more robust staffing of PN programs.

PubMed Disclaimer

Conflict of interest statement

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT

Disclosures provided by the authors and data availability statement (if applicable) are available with this article at DOI https://doi.org/10.1200/JOP.19.00230.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Patient Navigation in Cancer: The Business Case to Support Clinical Needs

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jop/site/ifc/journal-policies.html.

Ronald M. Kline

Stock and Other Ownership Interests: Las Vegas CyberKnife

Other Relationship: Centers for Medicare & Medicaid Services

Gabrielle B. Rocque

Consulting or Advisory Role: Pfizer, Roche

Research Funding: Carevive Systems, Genentech, Pfizer

Travel, Accommodations, Expenses: Genentech

Cynthia A. Cantril

Employment: Haymarket Media

Honoraria: Haymarket Media

Travel, Accommodations, Expenses: Haymarket Media

Howard A. Burris

Employment: HCA Healthcare/Sarah Cannon

Leadership: HCA Healthcare/Sarah Cannon

Stock and Other Ownership Interests: HCA Healthcare/Sarah Cannon

Consulting or Advisory Role: Mersana (Inst), AstraZeneca (Inst), FORMA Therapeutics (Inst), Janssen (Inst), Novartis (Inst), Roche (Inst), MedImmune (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), Incyte (Inst), Boehringer Ingelheim (Inst), Eisai (Inst), Tolero Pharmaceuticals (Inst)

Research Funding: Roche (Inst), Bristol-Myers Squibb (Inst), Incyte (Inst), AstraZeneca (Inst), MedImmune (Inst), Macrogenics (Inst), Novartis (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), Seattle Genetics (Inst), Merck (Inst), Celgene (Inst), Agios (Inst), Jounce Therapeutics (Inst), Moderna Therapeutics (Inst), CytomX Therapeutics (Inst), GlaxoSmithKline (Inst), Verastem (Inst), Tesaro (Inst), Immunocore (Inst), Takeda (Inst), Millennium (Inst), BioMed Valley Discoveries (Inst), TG Therapeutics (Inst), Loxo (Inst), Vertex (Inst), eFFECTOR Therapeutics (Inst), Janssen (Inst), Gilead Sciences (Inst), BioAtla (Inst), CicloMed (Inst), Harpoon Therapeutics (Inst), Jiangsu Hengrui Medicine (Inst), Arch (Inst), Kyocera (Inst), Arvinas (Inst), Revolution Medicines (Inst)

Expert Testimony: Novartis

Lawrence N. Shulman

Research Funding: Celgene

No other potential conflicts of interest were reported.

Similar articles

Cited by

References

    1. Oncology Nursing Society; Association of Oncology Social Work; National Association of Social Workers: Oncology Nursing Society, the Association of Oncology Social Work, and the National Association of Social Workers joint position on the role of oncology nursing and oncology social work in patient navigation. Oncol Nurs Forum 37:251–252, 2010 - PubMed
    1. Freeman HP: Patient navigation: A community based strategy to reduce cancer disparities. J Urban Health 83:139–141, 2006 - PMC - PubMed
    1. Rocque G: What is the role of symptom management and patient-reported outcomes in adherence to aromatase inhibitors? J Clin Oncol 36:308–309, 2018 - PubMed
    1. Wells KJ, Battaglia TA, Dudley DJ, et al.: Patient navigation: State of the art or is it science? Cancer 113:1999–2010, 2008 - PMC - PubMed
    1. Paskett ED, Harrop JP, Wells KJ: Patient navigation: An update on the state of the science. CA Cancer J Clin 61:237–249, 2011 - PMC - PubMed

MeSH terms